{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:50:43Z","timestamp":1761519043745},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2012,12,8]],"date-time":"2012-12-08T00:00:00Z","timestamp":1354924800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Causes Control"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s10552-012-0122-8","type":"journal-article","created":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T06:16:34Z","timestamp":1354860994000},"page":"365-371","source":"Crossref","is-referenced-by-count":21,"title":["Use of antihypertensive medications and breast cancer risk"],"prefix":"10.1007","volume":"24","author":[{"given":"Babette S.","family":"Saltzman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noel S.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiva","family":"Sieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette L.","family":"Fitzpatrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"McTiernan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet R.","family":"Daling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher I.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,8]]},"reference":[{"issue":"8","key":"122_CR1","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8<1438::AID-CNCR11>3.0.CO;2-6","volume":"80","author":"AL Fitzpatrick","year":"1997","unstructured":"Fitzpatrick AL, Daling JR, Furberg CD, Kronmal RA, Weissfeld JL (1997) Use of calcium channel blockers and breast carcinoma risk in postmenopausal women. Cancer 80(8):1438\u20131447. doi: 10.1002\/(SICI)1097-0142(19971015)80:8<1438:AID-CNCR11>3.0.CO;2-6","journal-title":"Cancer"},{"issue":"9026","key":"122_CR2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(96)04277-8","volume":"348","author":"M Pahor","year":"1996","unstructured":"Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, Wallace RB, Havlik RJ (1996) Calcium-channel blockade and incidence of cancer in aged populations. Lancet 348(9026):493\u2013497. doi: 10.1016\/S0140-6736(96)04277-8","journal-title":"Lancet"},{"issue":"8","key":"122_CR3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/pds.910","volume":"13","author":"A Gonzalez-Perez","year":"2004","unstructured":"Gonzalez-Perez A, Ronquist G, Garcia Rodriguez LA (2004) Breast cancer incidence and use of antihypertensive medication in women. Pharmacoepidemiol Drug Saf 13(8):581\u2013585. doi: 10.1002\/pds.910","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"122_CR4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/sj.jhh.1002075","volume":"20","author":"JA Largent","year":"2006","unstructured":"Largent JA, McEligot AJ, Ziogas A, Reid C, Hess J, Leighton N, Peel D, Anton-Culver H (2006) Hypertension, diuretics and breast cancer risk. J Hum Hypertens 20(10):727\u2013732. doi: 10.1038\/sj.jhh.1002075","journal-title":"J Hum Hypertens"},{"issue":"7","key":"122_CR5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/cncr.11663","volume":"98","author":"CI Li","year":"2003","unstructured":"Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR (2003) Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65\u201379\u00a0years. Cancer 98(7):1504\u20131513. doi: 10.1002\/cncr.11663","journal-title":"Cancer"},{"issue":"9051","key":"122_CR6","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0140-6736(97)80084-0","volume":"349","author":"H Jick","year":"1997","unstructured":"Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR (1997) Calcium-channel blockers and risk of cancer. Lancet 349(9051):525\u2013528. doi: 10.1016\/S0140-6736(97)80084-0","journal-title":"Lancet"},{"issue":"2","key":"122_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1007731210985","volume":"12","author":"M Jonas","year":"1998","unstructured":"Jonas M, Goldbourt U, Boyko V, Mandelzweig L, Behar S, Reicher-Reiss H (1998) Nifedipine and cancer mortality: ten-year follow-up of 2607 patients after acute myocardial infarction. Cardiovasc Drugs Ther 12(2):177\u2013181","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"122_CR8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/archinte.160.3.349","volume":"160","author":"CR Meier","year":"2000","unstructured":"Meier CR, Derby LE, Jick SS, Jick H (2000) Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 160(3):349\u2013353","journal-title":"Arch Intern Med"},{"issue":"5","key":"122_CR9","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.HYP.29.5.1091","volume":"29","author":"JH Olsen","year":"1997","unstructured":"Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL, Andersen M, Fraumeni JF Jr, Olsen J (1997) Cancer risk in users of calcium channel blockers. Hypertension 29(5):1091\u20131094","journal-title":"Hypertension"},{"issue":"13","key":"122_CR10","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","volume":"279","author":"L Rosenberg","year":"1998","unstructured":"Rosenberg L, Rao RS, Palmer JR, Strom BL, Stolley PD, Zauber AG, Warshauer ME, Shapiro S (1998) Calcium channel blockers and the risk of cancer. JAMA 279(13):1000\u20131004","journal-title":"JAMA"},{"issue":"1","key":"122_CR11","first-page":"165","volume":"89","author":"HT Sorensen","year":"2000","unstructured":"Sorensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, Baron JA (2000) Cancer risk and mortality in users of calcium channel blockers. A cohort study Cancer 89(1):165\u2013170. doi: 10.1002\/1097-0142(20000701)89:1<165:AID-CNCR21>3.0.CO;2-G","journal-title":"A cohort study Cancer"},{"key":"122_CR12","unstructured":"Michels KB, Rosner BA, Walker AM, Stampfer MJ, Manson JE, Colditz GA, Hennekens CH, Willett WC (1998) Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of US. women: the nurses\u2019 health study. Cancer 83 (9):2003\u20132007. doi: 10.1002\/(SICI)1097-0142(19981101)83:9<2003:AID-CNCR17>3.0.CO;2-3"},{"issue":"3","key":"122_CR13","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-005-9091-x","volume":"97","author":"JP Fryzek","year":"2006","unstructured":"Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Norgaard M, McLaughlin JK, Friis S (2006) A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 97(3):231\u2013236. doi: 10.1007\/s10549-005-9091-x","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"122_CR14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/1047-2797(91)90005-W","volume":"1","author":"LP Fried","year":"1991","unstructured":"Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, Kuller LH, Manolio TA, Mittelmark MB, Newman A et al (1991) The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1(3):263\u2013276","journal-title":"Ann Epidemiol"},{"issue":"4","key":"122_CR15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/1047-2797(93)90062-9","volume":"3","author":"GS Tell","year":"1993","unstructured":"Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO (1993) Recruitment of adults 65\u00a0years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 3(4):358\u2013366","journal-title":"Ann Epidemiol"},{"issue":"16","key":"122_CR16","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1161\/01.CIR.97.16.1540","volume":"97","author":"KB Michels","year":"1998","unstructured":"Michels KB, Rosner BA, Manson JE, Stampfer MJ, Walker AM, Willett WC, Hennekens CH (1998) Prospective study of calcium channel blocker use, cardiovascular disease, and total mortality among hypertensive women: the Nurses\u2019 Health Study. Circulation 97(16):1540\u20131548","journal-title":"Circulation"},{"issue":"8","key":"122_CR17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jama.1995.03530080036038","volume":"274","author":"BM Psaty","year":"1995","unstructured":"Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW et al (1995) The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 274(8):620\u2013625","journal-title":"JAMA"},{"issue":"7","key":"122_CR18","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0895-7061(96)00219-1","volume":"9","author":"JR Daling","year":"1996","unstructured":"Daling JR (1996) Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 9(7):713\u2013714","journal-title":"Am J Hypertens"},{"issue":"7","key":"122_CR19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0895-7061(96)00186-0","volume":"9","author":"M Pahor","year":"1996","unstructured":"Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ (1996) Do calcium channel blockers increase the risk of cancer? Am J Hypertens 9(7):695\u2013699","journal-title":"Am J Hypertens"},{"issue":"10","key":"122_CR20","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1002\/(SICI)1097-0142(19990515)85:10<2093::AID-CNCR1>3.0.CO;2-E","volume":"85","author":"RP Mason","year":"1999","unstructured":"Mason RP (1999) Effects of calcium channel blockers on cellular apoptosis: implications for carcinogenic potential. Cancer 85(10):2093\u20132102. doi: 10.1002\/(SICI)1097-0142(19990515)85:10<2093:AID-CNCR1>3.0.CO;2-E","journal-title":"Cancer"},{"issue":"11","key":"122_CR21","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/0277-5379(91)90018-9","volume":"27","author":"P Correale","year":"1991","unstructured":"Correale P, Tagliaferri P, Celio L, Genua G, Montagnani S, Bianco AR (1991) Verapamil upregulates sensitivity of human colon and breast cancer cells to LAK-cytotoxicity in vitro. Eur J Cancer 27(11):1393\u20131395","journal-title":"Eur J Cancer"},{"issue":"4","key":"122_CR22","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1179\/joc.1996.8.4.295","volume":"8","author":"CV Timcheva","year":"1996","unstructured":"Timcheva CV, Todorov DK (1996) Does verapamil help overcome multidrug resistance in tumor cell lines and cancer patients? J Chemother 8(4):295\u2013299","journal-title":"J Chemother"},{"issue":"9","key":"122_CR23","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/0006-2952(94)90550-9","volume":"47","author":"V Gupta","year":"1994","unstructured":"Gupta V, Kamath N, Tkalcevic GT, Singh SV (1994) Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. Biochem Pharmacol 47(9):1701\u20131704","journal-title":"Biochem Pharmacol"},{"key":"122_CR24","author":"TL Assimes","year":"2008","unstructured":"Assimes TL, Elstein E, Langleben A, Suissa S (2008) Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol Drug Saf. doi: 10.1002\/pds.1656","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Cancer Causes &amp; Control"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-012-0122-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10552-012-0122-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10552-012-0122-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T17:06:18Z","timestamp":1559235978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10552-012-0122-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,8]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["122"],"URL":"https:\/\/doi.org\/10.1007\/s10552-012-0122-8","relation":{},"ISSN":["0957-5243","1573-7225"],"issn-type":[{"value":"0957-5243","type":"print"},{"value":"1573-7225","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,8]]}}}